Volume4, Issue0 (2021) | undefined

Cancer Drug Resistance

Search Log In

Editor-in-Chief: Godefridus J. Peters

Indexing: ESCI, PMC, Scopus, CAS, CNKI, Dimensions, Lens, Embase,

Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)] Submission to first decision: 10 days

Hot Keywords

ResistanceDrug deliveryNanomedicineTumor microenvironmentImmune checkpoint inhibitorsTarget therapyImmunotherapyRadiotherapyFerroptosisPARP inhibitorsMYCABC transportersAutophagyMetabolismMechanismsPrecision medicineExtracellular vesiclesStem cellBiomarkerOvarian cancerRenal cell carcinomaProstate cancerBreast cancerColorectal cancerMyeloid leukemiaNon-small cell lung cancerPancreatic cancerHead and neck cancerSquamous cell carcinomaMitochondria

Home

About

Publish with us

Articles

Special Issues

Special Collections

Volumes

Pre-onlines

Features

Home Articles Special Issues Volumes Webinars Videos

Cancer Drug Resistance

Editor-in-Chief: Godefridus J. Peters

Journal Rank: Impact Factor 2023: 4.6 - Q1 (ONCOLOGY); CiteScore 2023: 6.6 - Q1 [Pharmacology(medical)]

Submission to first decision: 10 days

Home Articles Special Issues Volumes Webinars Videos

Home Volumes

Volume

Table of Contents (68 articles)

The role of extracellular vesicles in acquisition of resistance to therapy in glioblastomas

Anudeep Yekula, ... Leonora Balaj

Pages 1-16

Mechanisms of temozolomide resistance in glioblastoma - a comprehensive review

Neha Singh, ... Sandeep Mittal

Pages 17-43

Perspectives of nano-carrier drug delivery systems to overcome cancer drug resistance in the clinics

Anna Ulldemolins, ... Simo Schwartz Jr

Pages 44-68

Natural products as a means of overcoming cisplatin chemoresistance in bladder cancer

Ganeshkumar Rajendran, ... Benjamin L. Woolbright

Pages 69-84

P53-regulated autophagy and its impact on drug resistance and cell fate

Daeun Shim, ... Carl G. Maki

Pages 85-95

Oxidative stress and redox signaling in CRPC progression: therapeutic potential of clinically-tested Nrf2-activators

Debasis Mondal, ... Syed S. A. Quadri

Pages 96-124

Resistance to venetoclax and hypomethylating agents in acute myeloid leukemia

Antoine N. Saliba

Antoine N. Saliba

, ... Scott H. Kaufmann

Pages 125-142

Metabolic reprogramming as an emerging mechanism of resistance to endocrine therapies in prostate cancer

Paolo Chetta, Giorgia Zadra

Pages 143-162

Key genes and drug delivery systems to improve the efficiency of chemotherapy

Zally Torres-Martinez, ... Kai Griebenow

Pages 163-191

Albumin nanoformulations as an innovative solution to overcome doxorubicin chemoresistance

Federica Bessone, ... Roberta Cavalli

Pages 192-207

A bendamustine resistance gene signature in diffuse large B-cell lymphoma and multiple myeloma

Issa Ismail Issa, ... Karen Dybkær

Pages 208-222

Evaluation of the reducing potential of PSMA-containing endosomes by FRET imaging

Chelvam Venkatesh, ... Philip S. Low

Pages 223-232

Characterization of acquired nutlin-3 resistant non-small cell lung cancer cells

Christophe Deben, ... Patrick Pauwels

Pages 233-243

Exploiting DNA repair pathways for tumor sensitization, mitigation of resistance, and normal tissue protection in radiotherapy

Jac A. Nickoloff, ... Takamitsu A. Kato

Pages 244-263

Nanocarrier drug resistant tumor interactions: novel approaches to fight drug resistance in cancer

Aleksandra Benko, ... Thomas J. Webster

Pages 264-297

Curcumin: reclaiming the lost ground against cancer resistance

Siraj Shaikh, ... Mujahid Yusufi

Mujahid Yusufi

Pages 298-320

Regulation of cancer stem cells in triple negative breast cancer

Norman Fultang, ... Bela Peethambaran

Pages 321-342

Carbonic anhydrase XII inhibition overcomes P-glycoprotein-mediated drug resistance: a potential new combination therapy in cancer

Kathryn F. Tonissen, Sally-Ann Poulsen

Pages 343-355

Statins and endocrine resistance in breast cancer

Tara Hyder, ... Adam M. Brufsky

Pages 356-364

The emerging roles of E3 ubiquitin ligases in ovarian cancer chemoresistance

Yang Meng, ... Junhong Han

Pages 365-381

Imaging methods to evaluate tumor microenvironment factors affecting nanoparticle drug delivery and antitumor response

Amber S. Moody, ... William C. Zamboni

William C. Zamboni

Pages 382-413

DNA direct reversal repair and alkylating agent drug resistance

Roberto Gutierrez, Timothy R. O’Connor

Pages 414-423

Teaching an old dog new tricks: reactivated developmental signaling pathways regulate ABCB1 and chemoresistance in cancer

Wing-Kee Lee, Thévenod Frank

Pages 424-452

History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications

Franco Muggia, Andrea Bonetti

Pages 453-462

Liposome co-encapsulation of anti-cancer agents for pharmacological optimization of nanomedicine-based combination chemotherapy

Alberto Gabizon

Alberto Gabizon

, ... Hilary Shmeeda

Pages 463-484

ABCA1 is associated with the development of acquired chemotherapy resistance and predicts poor ovarian cancer outcome

Wanqi Wang, ... Carmela Ricciardelli

Carmela Ricciardelli

Pages 485-502

UCP2 - Taking the heat out of P-glycoprotein?

Richard Callaghan

Richard Callaghan

, Mary Board

Pages 503-511

Overcoming drug resistance in glioblastoma: new options in sight?

Joanna Kopecka, Chiara Riganti

Chiara Riganti

Pages 512-516

Research advances and new challenges in overcoming triple-negative breast cancer

Yu Zong, Mark Pegram

Pages 517-542

Emerging RAS-directed therapies for cancer

Michael Conroy

Michael Conroy

, ... Austin G. Duffy

Pages 543-558

The implication of liquid biopsies to predict chemoresistance in pancreatic cancer

Elisabetta Pietri, ... Ingrid Garajová

Pages 559-572

Targeting the PI3K/AKT/mTOR pathway in epithelial ovarian cancer, therapeutic treatment options for platinum-resistant ovarian cancer

Natasha Rinne, ... Paula Cunnea

Pages 573-595

Targeting mTOR and eIF4E: a feasible scenario in ovarian cancer therapy

Alice Romagnoli, ... Daniele Di Marino

Pages 596-606

Mechanisms of resistance to FGFR1 inhibitors in FGFR1-driven leukemias and lymphomas: implications for optimized treatment

John K. Cowell, Tianxiang Hu

Pages 607-619

ATP-binding cassette transporters at the zebrafish blood-brain barrier and the potential utility of the zebrafish as an in vivo model

Jordan M. Hotz, ... Michael M. Gottesman

Pages 620-633

Proteasomal adaptations to FDA-approved proteasome inhibitors: a potential mechanism for drug resistance?

Kyung Bo Kim

Pages 634-645

Epstein-Barr virus-associated post-transplant lymphoproliferative disorders: beyond chemotherapy treatment

Sanam Shahid, Susan E. Prockop

Pages 646-664

Drug resistance in targeted cancer therapies with RAF inhibitors

Ufuk Degirmenci, ... Jiancheng Hu

Pages 665-683

Cancer stem cells, epithelial-mesenchymal transition, ATP and their roles in drug resistance in cancer

Haiyun Zhang, ... Xiaozhuo Chen

Pages 684-709

Clinical significance of the loss of CD20 antigen on tumor cells in patients with relapsed or refractory follicular lymphoma

Jean-Marie Michot, ... Vincent Ribrag

Pages 710-718

Protective autophagy by thymidine causes resistance to rapamycin in colorectal cancer cells in vitro

I.V. Bijnsdorp, Godefridus J. Peters

Pages 719-727

Favorable clinical outcomes of checkpoint inhibitor-based combinations after progression with immunotherapy in advanced non-small cell lung cancer

Xin Yu, ... Chunxia Su

Chunxia Su

Pages 728-739

Cost-effectiveness of Osimertinib in activating epidermal growth factor receptor gene (EGFR)-mutations in first-line for advanced non-small cell lung cancer

Jacopo Giuliani, Andrea Bonetti

Pages 740-744

Advances in preclinical evaluation of experimental antibody-drug conjugates

Scott K. Lyons, ... Lloyd C. Trotman

Pages 745-754

Tackling cisplatin resistance in ovarian cancer: what can we do?

Paola Perego

Paola Perego

Pages 755-757

Targeting DNA topoisomerases: past & future

William H. Gmeiner, Robert C. A. M. van Waardenburg

Pages 758-761

Experimental models of endocrine responsive breast cancer: strengths, limitations, and use

Robert Clarke, ... Surojeet Sengupta

Pages 762-783

The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors

Jason Goebel, ... Christine A. Hrycyna

Pages 784-804

Notch signaling in female cancers: a multifaceted node to overcome drug resistance

Maria V. Giuli, ... Saula Checquolo

Pages 805-836

Targeting DNA repair pathways to overcome cancer drug resistance

Robert C.A.M. van Waardenburg

Robert C.A.M. van Waardenburg

, Eddy S. Yang

Pages 837-841

MYC inhibitors in multiple myeloma

Sandra Martínez-Martín, Laura Soucek

Pages 842-865

The aqueous extract of brucea javanica reduces tumorigenicity of human lung cancer tumorspheres

Seung-Hun Kim, ... Kang Fang

Pages 866-880

Overcoming acquired chemo-resistance to gemcitabine: implications from the perspective of multi-modal therapy including surgery for pancreatic cancer

Fuyuhiko Motoi

Pages 881-884

Recent advances in tumor-targeting chemotherapy drugs

Iwao Ojima

Iwao Ojima

Pages 885-887

Expression of histone deacetylase (HDAC) family members in bortezomib-refractory multiple myeloma and modulation by panobinostat

Tiewei Cheng, ... Joya Chandra

Pages 888-902

Erratum: P53-regulated autophagy and its impact on drug resistance and cell fate

Daeun Shim, ... Carl G. Maki

Pages 903-

SF3B1 modulators affect key genes in metastasis and drug influx: a new approach to fight pancreatic cancer chemoresistance

Ornella Randazzo, ... Elisa Giovannetti

Pages 904-922

The HGF/c-MET axis as a potential target to overcome survival signals and improve therapeutic efficacy in multiple myeloma

Paolo Giannoni, Daniela de Totero

Pages 923-933

Overview of microRNAs as liquid biopsy biomarkers for colorectal cancer sub-type profiling and chemoresistance

Alfred Buhagiar, ... Duncan Ayers

Pages 934-945

Cellular irinotecan resistance in colorectal cancer and overcoming irinotecan refractoriness through various combination trials including DNA methyltransferase inhibitors: a review

Shogo Ozawa, ... Wataru Habano

Pages 946-964

Barriers to achieving a cure in lymphoma

Swetha Kambhampati Thiruvengadam, ... Wing C. Chan

Pages 965-983

Targeting of PI3K/AKT signaling and DNA damage response in acute myeloid leukemia: a novel therapeutic strategy to boost chemotherapy response and overcome resistance

Montserrat Estruch, ... Kim Theilgaard-Mönch

Pages 984-995

Adjuvant role of a T-type calcium channel blocker, TTA-A2, in lung cancer treatment with paclitaxel

Neema Kumari

Neema Kumari

, ... Subha Narayan Rath

Pages 996-1007

Gene expression profiling as a prognostic tool in multiple myeloma

Harmony Black, Siobhan Glavey

Siobhan Glavey

Pages 1008-1018

EGFR/BRAF/MEK co-inhibition for EGFR-mutated lung adenocarcinoma patients with an acquired BRAF^V600E mutation: a case report and review of literature

Ran Zeng, ... Yi Xiang

Pages 1019-1027

Overcoming drug resistance by targeting protein homeostasis in multiple myeloma

Maria Moscvin

Maria Moscvin

, ... Giada Bianchi

Pages 1028-1046

Shenmai injection enhances cisplatin-induced apoptosis through regulation of Mfn2-dependent mitochondrial dynamics in lung adenocarcinoma A549/DDP cells

Yushi Chen, ... Chun Wang

Pages 1047-1060

Using cfRNA as a tool to evaluate clinical treatment outcomes in patients with metastatic lung cancers and other tumors

Luis E. Raez, ... Peter Danenberg

Pages 1061-1071

Actions for 0 selected articles

Cancer Drug Resistance

ISSN 2578-532X (Online)

editorial@cdrjournal.com

Navigation

Follow Us

LinkedIn
Twitter
WeChat

Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/cancer-drug-resistance

Portico

All published articles will preserved here permanently:

https://www.portico.org/publishers/oae/

partners@oaepublish.com

Discover Content

Language Editing

Layout & Production

Graphical Abstracts

Video Abstracts

Conference Organizer

Strategic Collaborators

Follow OAE

© 2016-2025 OAE Publishing Inc., except certain content provided by third parties

Privacy Cookies Terms of Service